Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2019
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 28 Aug 2019 Status changed from not yet recruiting to recruiting.
- 30 May 2019 Planned initiation date changed from 31 Oct 2018 to 30 Jun 2019.
- 10 Sep 2018 New trial record